Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 490 | 614 | 589 | 763 | 1,027 |
| Receivables | N/A | N/A | 1 | 0 | 1 |
| TOTAL | $977 | $760 | $800 | $1,009 | $1,365 |
| Non-Current Assets | |||||
| PPE Net | 5 | 5 | 8 | 10 | 12 |
| Other Non-Current Assets | 25 | 37 | 49 | 60 | 72 |
| TOTAL | $30 | $42 | $56 | $70 | $84 |
| Total Assets | $1,006 | $802 | $856 | $1,079 | $1,449 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 2,943 | N/A |
| Accounts payable and accrued liabilities | 1,107 | 1,381 | 1,322 | 1,370 | 1,676 |
| Accrued Expenses | 173 | 134 | 151 | 152 | 146 |
| TOTAL | $6,976 | $6,225 | $8,370 | $8,516 | $9,017 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 336 | 350 | 460 | 715 | 953 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 13 | 25 |
| TOTAL | $N/A | $N/A | $N/A | $13 | $25 |
| Total Liabilities | $6,976 | $6,225 | $8,370 | $8,529 | $9,042 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 420,280 | 420,280 | 419,907 | 419,522 | 419,522 |
| Common Shares | 420 | 420 | 420 | 420 | 420 |
| Retained earnings | -257,423 | -255,056 | -254,041 | -253,195 | -252,690 |
| Other shareholders' equity | -70 | -46 | -48 | -50 | -48 |
| TOTAL | $-5,969 | $-5,423 | $-7,513 | $-7,450 | $-7,593 |
| Total Liabilities And Equity | $1,006 | $802 | $856 | $1,079 | $1,449 |